2-Ethoxy-4-propan-2-ylpyrimidine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Ethoxy-4-propan-2-ylpyrimidine
• 英文别名: 2-ethoxy-4-propan-2-ylpyrimidine
• 化学式: C₉H₁₄N₂O
• 分子量: 166.22
• InChiKey: XOZXVXXWLBLVND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators
  申请人：GlaxoSmithKline, LLC

  公开号：US20140249147A1

  公开（公告）日：2014-09-04

  Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided, are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新型的取代双环氮杂杂环类Sirtuin调节化合物及其使用方法。这些Sirtuin调节化合物可用于增加细胞寿命，治疗和/或预防各种疾病和疾病，包括与衰老或压力有关的疾病或疾病、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块性疾病、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或疾病。同时，还提供了包含Sirtuin调节化合物和另一种治疗剂的组合物。
• [EN] NITROGEN-SUBSTITUTED HETEROCYCLIC THIOPHENE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS THIOPHÈNE HÉTÉROCYCLIQUES SUBSTITUÉS PAR AZOTE ET LEUR UTILISATION<br/>[ZH] 氮取代杂环噻吩类化合物及其用途
  申请人：WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY

  公开号：WO2022100623A1

  公开（公告）日：2022-05-19

  公开了一类有效拮抗LPAR的新化合物，其为下式所示化合物，或者下式示化合物的立体异构体、水合物、溶剂化物、药学可接受的盐或前药：(I)
• Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds
  申请人：PHARMAKEA, INC.

  公开号：US11345676B2

  公开（公告）日：2022-05-31

  Described herein are ASK1 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with ASK1 activity.

  本文描述了 ASK1 抑制剂、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 ASK1 活性相关的病症、疾病或失调的方法。
• SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline LLC

  公开号：EP2768509B1

  公开（公告）日：2017-03-22
• APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS
  申请人：PHARMAKEA, INC.

  公开号：US20200048218A1

  公开（公告）日：2020-02-13

  Described herein are ASK1 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with ASK1 activity.